We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

114 hedge funds and large institutions have $423M invested in Concert Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

327% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 11

93% more capital invested

Capital invested by funds: $219M → $423M (+$204M)

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

59% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $769K

44% more funds holding

Funds holding: 79 → 114 (+35)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
114
Holders Change
+35
Holders Change %
+44.3%
% of All Funds
2.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
47
Increased
37
Reduced
23
Closed
11
Calls
$1.22M
Puts
$769K
Net Calls
+$452K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$14.3M
2
BlackRock
BlackRock
New York
+$13.1M
3
Millennium Management
Millennium Management
New York
+$10.1M
4
BC
Boxer Capital
California
+$8.05M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$6M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$26.9M
2
BI
BVF Inc
California
-$23.5M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$5.43M
4
LSC
Lyon Street Capital
California
-$5.21M
5
SM
Senvest Management
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
101
BNP Paribas Financial Markets
France
$96.3K +$41.1K +2,043 +122%
Parallax Volatility Advisers
102
Parallax Volatility Advisers
California
$95K +$74.2K +3,687 New
DCM
103
Delpha Capital Management
New York
$55K +$43K +2,137 New
PMFA
104
Plante Moran Financial Advisors
Michigan
$52K +$20.1K +1,000 +100%
AIP
105
Ameritas Investment Partners
Nebraska
$40K +$6.85K +340 +29%
EA
106
Edge Advisors
Georgia
$25K +$20.1K +1,000 New
SEI Investments
107
SEI Investments
Pennsylvania
$22K +$17.3K +857 New
Bank of Montreal
108
Bank of Montreal
Ontario, Canada
$21K – – –
LTFS
109
Ladenburg Thalmann Financial Services
Florida
$7K +$5.34K +265 New
MAM
110
Meeder Asset Management
Ohio
$5K -$242 -12 -5%
AssetMark Inc
111
AssetMark Inc
California
$3K +$2.09K +104 New
MA
112
MUFG Americas
New York
$2K -$3.75K -186 -73%
HR
113
Howe & Rusling
New York
$1K +$805 +40 New
Alyeska Investment Group
114
Alyeska Investment Group
Illinois
– -$5.43M -368,243 Closed
PNC Financial Services Group
115
PNC Financial Services Group
Pennsylvania
– -$3.62M -245,337 Closed
Principal Financial Group
116
Principal Financial Group
Iowa
– -$1.75M -118,600 Closed
Point72 Asset Management
117
Point72 Asset Management
Connecticut
– -$843K -57,134 Closed
Simplex Trading
118
Simplex Trading
Illinois
– -$303K -15,040 -100%
SG Americas Securities
119
SG Americas Securities
New York
– -$153K -10,367 Closed
NFA
120
Nationwide Fund Advisors
Ohio
– -$145K -9,861 Closed
RFS
121
Rockefeller Financial Services
New York
– -$141K -9,533 Closed
TRCT
122
Tower Research Capital (TRC)
New York
– -$51K -3,456 Closed
CG
123
Cutler Group
California
– -$33.7K -1,673 Closed
PCM
124
Prelude Capital Management
New York
– -$10K -700 Closed
PHK
125
Point72 Hong Kong
Hong Kong
– -$2K -114 Closed
1 2 3 4
5

CNCE Hedge Fund Activity: Q4 2017 in Review

114 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2017, worth a combined $423M — up 93% from $219M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new CNCE positions and 11 closed out — a net gain of 36 holders — while 37 added to existing stakes and 23 trimmed.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $26.9M.

  • 114 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2017, up from 79 in Q3 2017.
  • Funds reported $423M of Concert Pharmaceuticals, Inc. stock for Q4 2017, up 93% quarter-over-quarter.
  • 47 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2017 and 11 closed out, a net change of +36 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2017 was Laurion Capital Management, an estimated $14.3M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2017 was Great Point Partners, an estimated $26.9M sold.

Based on aggregated 13F filings for Q4 2017.